Good Samaritan Hospital Corvallis
- Type
- Teaching hospital
- Where
- Corvallis, OR
- Medicare CCN
- 380014
- Received
- $326,146 in 87 records, 2020 ($99,321 general, $226,825 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: GOOD SAMARITAN HOSPITAL CORVALLIS Fuzzy (name and state)
- Plan sponsor: GOOD SAMARITAN HOSPITAL CORVALLIS Fuzzy (name and state)
- Federal award recipient: GOOD SAMARITAN HOSPITAL CORVALLIS Fuzzy (name and state)
- Nonprofit: GOOD SAMARITAN HOSPITAL CORVALLIS Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 22 | $99,321 |
| 2020 | Research payment | 65 | $226,825 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| HILL-ROM HOLDINGS, INC | 1 | $94,617 | 2020 |
| Incyte Corporation | 26 | $57,445 | 2020 |
| Merck Sharp & Dohme LLC | 5 | $53,190 | 2020 |
| Janssen Research & Development, LLC | 18 | $41,277 | 2020 |
| Novartis Pharmaceuticals Corporation | 4 | $25,425 | 2020 |
| Astellas Pharma Global Development | 1 | $18,890 | 2020 |
| Abbott Laboratories | 5 | $11,213 | 2020 |
| PUMA BIOTECHNOLOGY, INC. | 3 | $7,885 | 2020 |
| PFIZER INC. | 2 | $6,500 | 2020 |
| Eli Lilly and Company | 1 | $5,000 | 2020 |
| Medline Industries LP | 2 | $2,238 | 2020 |
| Medtronic MiniMed, Inc. | 3 | $1,250 | 2020 |
| LEICA MICROSYSTEMS INC. | 15 | $1,120 | 2020 |
| Olympus America Inc. | 1 | $95 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 65 | $226,825 |
| Charitable Contribution | 1 | $94,617 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 5 | $3,488 |
| Gift | 16 | $1,215 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-21 | Janssen Research & Development, LLC | $961 | Research payment | Cash or cash equivalent | A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenal | 2020 | |
| 2020-12-17 | LEICA MICROSYSTEMS INC. | $233 | Gift | Cash or cash equivalent | N/A Device, CANCER DIAGNOSTICS | 2020 | |
| 2020-12-17 | LEICA MICROSYSTEMS INC. | $6 | Gift | Cash or cash equivalent | N/A Device, CANCER DIAGNOSTICS | 2020 | |
| 2020-12-16 | Incyte Corporation | $1,000 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-12-15 | Medtronic MiniMed, Inc. | $225 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Minimed 670G System Device, Durable Pump | 2020 | |
| 2020-12-14 | Janssen Research & Development, LLC | $375 | Research payment | Cash or cash equivalent | A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenal | 2020 | |
| 2020-12-08 | Incyte Corporation | $17 | Research payment | Cash or cash equivalent | Evaluation Of Ruxolitinib And Azacytidine Combination As A Therapy For Patients With Myelofibrosis And Myelodysplastic S | 2020 | |
| 2020-12-03 | Janssen Research & Development, LLC | $4,071 | Research payment | Cash or cash equivalent | A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenal | 2020 | |
| 2020-12-01 | LEICA MICROSYSTEMS INC. | $24 | Gift | Cash or cash equivalent | N/A Device, CANCER DIAGNOSTICS | 2020 | |
| 2020-11-17 | LEICA MICROSYSTEMS INC. | $168 | Gift | Cash or cash equivalent | N/A Device, CANCER DIAGNOSTICS | 2020 | |
| 2020-11-11 | Incyte Corporation | $2,515 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-11-11 | Incyte Corporation | $520 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-11-11 | Incyte Corporation | $243 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-11-11 | Incyte Corporation | $105 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-11-11 | LEICA MICROSYSTEMS INC. | $3 | Gift | Cash or cash equivalent | N/A Device, CANCER DIAGNOSTICS | 2020 | |
| 2020-11-09 | LEICA MICROSYSTEMS INC. | $3 | Gift | Cash or cash equivalent | N/A Device, CANCER DIAGNOSTICS | 2020 | |
| 2020-11-03 | LEICA MICROSYSTEMS INC. | $24 | Gift | Cash or cash equivalent | N/A Device, CANCER DIAGNOSTICS | 2020 | |
| 2020-10-28 | Abbott Laboratories | $40 | Research payment | Cash or cash equivalent | Cardiovascular-Research only Device, Cardiac Arrhythmias and Heart Failure | MOre REsponse on Cardiac Resynchronization Therapy (CRT) with MultiPoint Pacing (MPP) | 2020 |
| 2020-10-27 | LEICA MICROSYSTEMS INC. | $179 | Gift | Cash or cash equivalent | N/A Device, CANCER DIAGNOSTICS | 2020 | |
| 2020-10-27 | LEICA MICROSYSTEMS INC. | $34 | Gift | Cash or cash equivalent | N/A Device, CANCER DIAGNOSTICS | 2020 | |
| 2020-10-26 | Janssen Research & Development, LLC | $4,641 | Research payment | Cash or cash equivalent | A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenal | 2020 | |
| 2020-10-26 | LEICA MICROSYSTEMS INC. | $153 | Gift | Cash or cash equivalent | N/A Device, CANCER DIAGNOSTICS | 2020 | |
| 2020-10-26 | LEICA MICROSYSTEMS INC. | $102 | Gift | Cash or cash equivalent | N/A Device, CANCER DIAGNOSTICS | 2020 | |
| 2020-10-26 | LEICA MICROSYSTEMS INC. | $95 | Gift | Cash or cash equivalent | N/A Device, CANCER DIAGNOSTICS | 2020 | |
| 2020-10-26 | LEICA MICROSYSTEMS INC. | $34 | Gift | Cash or cash equivalent | N/A Device, CANCER DIAGNOSTICS | 2020 | |
| 2020-10-26 | LEICA MICROSYSTEMS INC. | $31 | Gift | Cash or cash equivalent | N/A Device, CANCER DIAGNOSTICS | 2020 | |
| 2020-10-26 | LEICA MICROSYSTEMS INC. | $25 | Gift | Cash or cash equivalent | N/A Device, CANCER DIAGNOSTICS | 2020 | |
| 2020-10-14 | Medline Industries LP | $1,236 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Reprocessed Instruments Medical Supply, Reprocessing | 2020 | |
| 2020-10-12 | Janssen Research & Development, LLC | $2,447 | Research payment | Cash or cash equivalent | A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenal | 2020 | |
| 2020-10-01 | PFIZER INC. | $5,000 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB IN COMBINATION WITH PHYSICIANS CHOICE OF ENZALUT | 2020 |
| 2020-09-30 | Eli Lilly and Company | $5,000 | Research payment | Cash or cash equivalent | A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | 2020 | |
| 2020-09-17 | Abbott Laboratories | $1,600 | Research payment | Cash or cash equivalent | Cardiovascular-Research only Device, Cardiac Arrhythmias and Heart Failure | MOre REsponse on Cardiac Resynchronization Therapy (CRT) with MultiPoint Pacing (MPP) | 2020 |
| 2020-08-31 | Janssen Research & Development, LLC | $2,665 | Research payment | Cash or cash equivalent | A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenal | 2020 | |
| 2020-08-28 | PFIZER INC. | $1,500 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB IN COMBINATION WITH PHYSICIANS CHOICE OF ENZALUT | 2020 |
| 2020-08-19 | Abbott Laboratories | $2,305 | Research payment | Cash or cash equivalent | Cardiovascular-Research only Device, Cardiac Arrhythmias and Heart Failure | MOre REsponse on Cardiac Resynchronization Therapy (CRT) with MultiPoint Pacing (MPP) | 2020 |
| 2020-08-13 | Medtronic MiniMed, Inc. | $425 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Minimed 670G System Device, Durable Pump | 2020 | |
| 2020-08-06 | Janssen Research & Development, LLC | $500 | Research payment | Cash or cash equivalent | A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenal | 2020 | |
| 2020-08-03 | Merck Sharp & Dohme LLC | $26,055 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo controlled Study to Evaluate the Safety and Efficacy of Pemetrexed Platinum Chemotherapy | 2020 |
| 2020-07-30 | Janssen Research & Development, LLC | $2,447 | Research payment | Cash or cash equivalent | A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenal | 2020 | |
| 2020-07-20 | Merck Sharp & Dohme LLC | $657 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo controlled Study to Evaluate the Safety and Efficacy of Pemetrexed Platinum Chemotherapy | 2020 |
| 2020-07-09 | Janssen Research & Development, LLC | $3,290 | Research payment | Cash or cash equivalent | A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenal | 2020 | |
| 2020-06-22 | Janssen Research & Development, LLC | $110 | Research payment | Cash or cash equivalent | A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenal | 2020 | |
| 2020-06-17 | Incyte Corporation | $2,510 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-06-17 | Incyte Corporation | $1,509 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-06-17 | Incyte Corporation | $1,479 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-06-08 | Janssen Research & Development, LLC | $1,704 | Research payment | Cash or cash equivalent | A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenal | 2020 | |
| 2020-06-02 | Novartis Pharmaceuticals Corporation | $1,692 | Research payment | Cash or cash equivalent | PIQRAY Drug, ONCOLOGY | SOLAR1 A PHASE III RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF ALPELISIB IN COMBINATION WITH FULVESTRANT FOR MEN | 2020 |
| 2020-05-21 | Incyte Corporation | $1,422 | Research payment | Cash or cash equivalent | Noninterventional Epigenomic Mapping of CD34 plus Cells From Healthy Participants and Patients With Myelofibrosis (MF) a | 2020 | |
| 2020-05-14 | Novartis Pharmaceuticals Corporation | $7,937 | Research payment | Cash or cash equivalent | AIN457P Drug | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, PHASE III MULTICENTER STUDY OF INTRAVENOUS SECUKINUMAB T | 2020 |
| 2020-05-11 | Merck Sharp & Dohme LLC | $38 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo controlled Study to Evaluate the Safety and Efficacy of Pemetrexed Platinum Chemotherapy | 2020 |
| 2020-05-01 | Merck Sharp & Dohme LLC | $26,055 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo controlled Study to Evaluate the Safety and Efficacy of Pemetrexed Platinum Chemotherapy | 2020 |
| 2020-04-29 | Abbott Laboratories | $3,319 | Research payment | Cash or cash equivalent | Cardiovascular-Research only Device, Cardiac Arrhythmias and Heart Failure | MOre REsponse on Cardiac Resynchronization Therapy (CRT) with MultiPoint Pacing (MPP) | 2020 |
| 2020-04-28 | PUMA BIOTECHNOLOGY, INC. | $2,300 | Research payment | Cash or cash equivalent | NERLYNX Drug, ONCOLOGY | AN OPEN-LABEL STUDY TO CHARACTERIZE THE INCIDENCE AND SEVERITY OF DIARRHEA | 2020 |
| 2020-04-28 | PUMA BIOTECHNOLOGY, INC. | $110 | Research payment | Cash or cash equivalent | NERLYNX Drug, ONCOLOGY | AN OPEN-LABEL STUDY TO CHARACTERIZE THE INCIDENCE AND SEVERITY OF DIARRHEA | 2020 |
| 2020-04-22 | Incyte Corporation | $5,300 | Research payment | Cash or cash equivalent | Evaluation Of Ruxolitinib And Azacytidine Combination As A Therapy For Patients With Myelofibrosis And Myelodysplastic S | 2020 | |
| 2020-04-22 | Incyte Corporation | $1,012 | Research payment | Cash or cash equivalent | Evaluation Of Ruxolitinib And Azacytidine Combination As A Therapy For Patients With Myelofibrosis And Myelodysplastic S | 2020 | |
| 2020-04-22 | Incyte Corporation | $1,000 | Research payment | Cash or cash equivalent | Evaluation Of Ruxolitinib And Azacytidine Combination As A Therapy For Patients With Myelofibrosis And Myelodysplastic S | 2020 | |
| 2020-04-20 | Janssen Research & Development, LLC | $4,545 | Research payment | Cash or cash equivalent | A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenal | 2020 | |
| 2020-04-20 | Merck Sharp & Dohme LLC | $382 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo controlled Study to Evaluate the Safety and Efficacy of Pemetrexed Platinum Chemotherapy | 2020 |
| 2020-04-07 | Incyte Corporation | $600 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-04-02 | Janssen Research & Development, LLC | $743 | Research payment | Cash or cash equivalent | A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenal | 2020 | |
| 2020-03-26 | HILL-ROM HOLDINGS, INC | $94,617 | Charitable Contribution | In-kind items and services | Connex Vital Signs Monitor Device, Patient Vital Signs Monitoring | 2020 | |
| 2020-03-20 | Medtronic MiniMed, Inc. | $600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Minimed 670G System Device, Durable Pump | 2020 | |
| 2020-03-13 | Janssen Research & Development, LLC | $3,579 | Research payment | Cash or cash equivalent | A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenal | 2020 | |
| 2020-03-11 | Astellas Pharma Global Development | $18,890 | Research payment | Cash or cash equivalent | CRESEMBA Drug, HOSPITAL AND TRANSPLANT | OBSERVATIONAL DISEASE REGISTRY OF PATIENTS TREATED WITH SYSTEMIC MOLD-ACTIVE TRIAZOLES | 2020 |
| 2020-03-10 | Novartis Pharmaceuticals Corporation | $1,100 | Research payment | Cash or cash equivalent | ENTRESTO Drug, CARDIOVASCULAR | A 24 WEEK RANDOMIZED DOUBLE BLIND MULTI CENTER PARALLEL GROUP ACTIVE CONTROLLED STUDY TO EVALUATE THE EFFECT OF LCZ696 O | 2020 |
| 2020-03-02 | Janssen Research & Development, LLC | $2,317 | Research payment | Cash or cash equivalent | A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenal | 2020 | |
| 2020-02-17 | Medline Industries LP | $1,002 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Reprocessed Instruments Medical Supply, Reprocessing | 2020 | |
| 2020-02-13 | Incyte Corporation | $21,161 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-02-12 | Abbott Laboratories | $3,949 | Research payment | Cash or cash equivalent | Cardiovascular-Research only Device, Cardiac Arrhythmias and Heart Failure | MOre REsponse on Cardiac Resynchronization Therapy (CRT) with MultiPoint Pacing (MPP) | 2020 |
| 2020-02-11 | Olympus America Inc. | $95 | Gift | In-kind items and services | 2020 | ||
| 2020-02-03 | Janssen Research & Development, LLC | $5,032 | Research payment | Cash or cash equivalent | A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenal | 2020 | |
| 2020-01-28 | Incyte Corporation | $1,000 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-01-22 | Novartis Pharmaceuticals Corporation | $14,696 | Research payment | Cash or cash equivalent | COSENTYX Biological, IMMUNOLOGY | A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER STUDY OF SECUKINUMAB TO COMPARE 300 MG AND 150 MG AT WEEK 52 IN | 2020 |
| 2020-01-22 | Incyte Corporation | $14,085 | Research payment | Cash or cash equivalent | Evaluation Of Ruxolitinib And Azacytidine Combination As A Therapy For Patients With Myelofibrosis And Myelodysplastic S | 2020 | |
| 2020-01-22 | Incyte Corporation | $1,300 | Research payment | Cash or cash equivalent | Evaluation Of Ruxolitinib And Azacytidine Combination As A Therapy For Patients With Myelofibrosis And Myelodysplastic S | 2020 | |
| 2020-01-22 | Incyte Corporation | $250 | Research payment | Cash or cash equivalent | Evaluation Of Ruxolitinib And Azacytidine Combination As A Therapy For Patients With Myelofibrosis And Myelodysplastic S | 2020 | |
| 2020-01-20 | Janssen Research & Development, LLC | $1,500 | Research payment | Cash or cash equivalent | A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenal | 2020 | |
| 2020-01-16 | PUMA BIOTECHNOLOGY, INC. | $5,475 | Research payment | Cash or cash equivalent | NERLYNX Drug, ONCOLOGY | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF NERATINIB (HKI-272) AFTER TRASTUZUMAB IN WOMEN WITH EARLY-STAGE | 2020 |
| 2020-01-09 | Incyte Corporation | $176 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-01-09 | Incyte Corporation | $98 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-01-09 | Incyte Corporation | $57 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-01-09 | Incyte Corporation | $57 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-01-09 | Incyte Corporation | $22 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-01-09 | Incyte Corporation | $2 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-01-09 | Incyte Corporation | $0 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-01-06 | Janssen Research & Development, LLC | $350 | Research payment | Cash or cash equivalent | A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenal | 2020 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Corvallis, OR, county Benton County, OR, state Oregon; placed by its city name.
| Measure | Place (city or town) Corvallis, OR | County Benton County, OR | State Oregon |
|---|---|---|---|
| Population B01003 | 59,960 | 96,303 | 4,254,293 |
| Population, 2020 census P1 | 59,922 | 95,184 | 4,237,256 |
| Median age B01002 | 27.9 | 34.5 | 40.4 |
| Under 18 B01001 | 14.1% | 15.7% | 19.9% |
| 65 and over B01001 | 14.2% | 18.0% | 19.1% |
| Households B11001 | 23,980 | 38,537 | 1,718,422 |
| Foreign born B05002 | 12.7% | 9.9% | 9.8% |
| Median household income B19013 | $65,012 | $77,702 | $83,011 |
| Median family income B19113 | $116,107 | $115,974 | $102,281 |
| Per capita income B19301 | $40,092 | $45,624 | $45,612 |
| Poverty rate B17001 | 24.3% | 18.2% | 11.9% |
| Unemployment rate B23025 | 8.4% | 7.0% | 5.4% |
| Civilian labor force B23025 | 32,604 | 50,745 | 2,183,462 |
| Mean commute (minutes) B08013 | 16.1 | 19.6 | 23.0 |
| Bachelor's degree or higher B15003 | 61.4% | 54.2% | 36.8% |
| Housing units B25001 | 25,628 | 40,951 | 1,857,992 |
| Owner-occupied B25003 | 41.7% | 56.9% | 63.3% |
| Renters B25003 | 58.3% | 43.1% | 36.7% |
| Median home value B25077 | $502,900 | $513,000 | $477,600 |
| Median gross rent B25064 | $1,391 | $1,410 | $1,525 |
| White, not Hispanic B03002 | 72.5% | 76.2% | 71.4% |
| Black B03002 | 1.6% | 1.1% | 1.8% |
| Hispanic or Latino B03002 | 10.2% | 9.4% | 14.7% |
| Asian B03002 | 9.0% | 6.6% | 4.4% |
| American Indian and Alaska Native B03002 | 0.2% | 0.4% | 0.6% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Corvallis, OR.
Comments